The incidence of invasive fungal infections (IFI) has increased significantly in the last three decades due to a multitude of factors. IFI are associated with high mortality, therefore, the availability of a rapid and reliable screening test for initiation of appropriate antifungal therapy is needed. Culture-based diagnostic methods are often delayed due to the slow-growing nature of fungal pathogens and the poor sensitivity of these tests. 1,3-β-D-Glucan (BDG) is a component of most fungal cell walls and is shed into the bloodstream during an invasive infection. It has been shown to become positive at a median of 10 days before a definitive positive culture result is obtained.